8.22
Schlusskurs vom Vortag:
$8.39
Offen:
$8.42
24-Stunden-Volumen:
141.86K
Relative Volume:
0.10
Marktkapitalisierung:
$732.06M
Einnahmen:
$380.79M
Nettoeinkommen (Verlust:
$49.27M
KGV:
11.74
EPS:
0.7
Netto-Cashflow:
$10.68M
1W Leistung:
-0.79%
1M Leistung:
+28.16%
6M Leistung:
+128.19%
1J Leistung:
+327.86%
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
Firmenname
Amylyx Pharmaceuticals Inc
Sektor
Branche
Telefon
617-683-0917
Adresse
43 THORNDIKE STREET, CAMBRIDGE
Vergleichen Sie AMLX mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
AMLX
Amylyx Pharmaceuticals Inc
|
8.2124 | 701.54M | 380.79M | 49.27M | 10.68M | 0.70 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
474.55 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
572.17 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
329.15 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
581.33 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
294.94 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-07-10 | Fortgesetzt | Goldman | Buy |
2025-06-24 | Eingeleitet | Guggenheim | Buy |
2025-06-17 | Eingeleitet | Citigroup | Buy |
2025-05-30 | Eingeleitet | TD Cowen | Buy |
2025-04-07 | Hochstufung | Mizuho | Neutral → Outperform |
2024-11-18 | Hochstufung | Robert W. Baird | Neutral → Outperform |
2024-10-23 | Hochstufung | BofA Securities | Neutral → Buy |
2024-03-18 | Herabstufung | Mizuho | Buy → Neutral |
2024-03-11 | Herabstufung | Leerink Partners | Outperform → Market Perform |
2024-03-11 | Herabstufung | Robert W. Baird | Outperform → Neutral |
2024-03-08 | Herabstufung | Evercore ISI | Outperform → In-line |
2024-03-08 | Herabstufung | Goldman | Buy → Neutral |
2024-01-03 | Eingeleitet | Robert W. Baird | Outperform |
2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
2023-07-24 | Hochstufung | Goldman | Neutral → Buy |
2023-03-31 | Eingeleitet | Mizuho | Buy |
2023-01-05 | Eingeleitet | BofA Securities | Buy |
2022-05-25 | Eingeleitet | Citigroup | Buy |
2022-04-01 | Herabstufung | Goldman | Buy → Neutral |
Alle ansehen
Amylyx Pharmaceuticals Inc Aktie (AMLX) Neueste Nachrichten
Is Amylyx Pharmaceuticals Inc. a good long term investmentFree Buy/Sell Signal Notifications - Autocar Professional
Hypoglycemia Clinical, Companies, Therapeutic Assessment, - openPR.com
What analysts say about Amylyx Pharmaceuticals Inc. stockExceptional risk-adjusted gains - Autocar Professional
What drives Amylyx Pharmaceuticals Inc. stock priceHigh-return market picks - jammulinksnews.com
Published on: 2025-07-22 15:57:30 - jammulinksnews.com
autocarpro> 2025> What drives Amylyx Pharmaceuticals Inc. stock priceRobust financial gains - Autocar Professional
Amylyx Pharmaceuticals: High-Risk, High-Reward Biotech Play with Game-Changing Pipeline Catalysts in 2026 - AInvest
Amylyx Pharmaceuticals: A High-Risk Pipeline With Strong Upside Potential (NASDAQ:AMLX) - Seeking Alpha
Promising Potential of Amylyx Pharmaceuticals’ Avexitide Program Drives Buy Rating - TipRanks
How Amylyx Pharmaceuticals Inc. stock performs during market volatilityFree Exclusive Group - Newser
What makes Amylyx Pharmaceuticals Inc. stock price move sharplyVolume Spike Monitors - Newser
Amylyx Pharmaceuticals Shares Promising Avexitide Data for Post-Bariatric Hypoglycemia at ENDO 2025, Phase 3 Enrollment Nears Completion - Insider Monkey
Why Amylyx Pharmaceuticals Inc. stock attracts strong analyst attentionFree Capital Growth Strategies - Newser
AMYLYX ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
AMYLYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Amylyx Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
TD Cowen reiterates Buy rating on Amylyx stock, cites avexitide potential - Investing.com Nigeria
TD Cowen reiterates Buy rating on Amylyx stock, cites avexitide potential By Investing.com - Investing.com South Africa
Amylyx Drug Slashes Sugar Spikes Post-Weight Loss SurgeryAmylyx Pharmaceuticals (NASDAQ:AMLX) - Benzinga
Citi maintains Buy rating on Amylyx Pharmaceuticals stock after KOL event By Investing.com - Investing.com South Africa
Amylyx presents new exploratory analyses from avexitide trials for PBH - Yahoo Finance
Citi maintains Buy rating on Amylyx Pharmaceuticals stock after KOL event - Investing.com Nigeria
Amylyx Pharmaceuticals Reports Results of Phase 2b Post-Bariatric Hypoglycemia Clinical Trial - MarketScreener
Amylyx Pharma Gains Retail Buzz As Once-Daily Pill Cuts Severe Blood Sugar Crashes In Mid-Stage Trial - NewsBreak: Local News & Alerts
Transcript : Amylyx Pharmaceuticals, Inc.Special Call - MarketScreener
Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025 - BioSpace
Amylyx Pharmaceuticals (NASDAQ:AMLX) Upgraded at The Goldman Sachs Group - MarketBeat
Breakthrough Drug Cuts Dangerous Post-Bariatric Surgery Events by 64%: Phase 2 Trial Results Revealed - Stock Titan
Amylyx Pharmaceuticals (NASDAQ:AMLX) Raised to “Buy” at The Goldman Sachs Group - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Connect - ACCESS Newswire
Promising Potential of Avexitide Drives Amylyx Pharmaceuticals’ Growth Prospects - TipRanks
Goldman Sachs resumes Amylyx stock coverage with Buy rating on avexitide potential - Investing.com Nigeria
Finanzdaten der Amylyx Pharmaceuticals Inc-Aktie (AMLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):